Ameriprise, Amundi add to their European rosters
Ameriprise, Amundi add to their European rosters
Firms target EMEA, ETF expansions in new deals with BMO, Lyxor
Ameriprise Financial Inc. and Amundi made moves earlier this month to bolster their European capabilities.
Ameriprise Financial signed a definitive agreement to acquire BMO Financial Group s EMEA money management business in a £615 million ($850 million) all-cash deal, while Amundi announced it is in exclusive negotiations with Lyxor Asset Management s parent company to acquire the European exchange-traded funds specialist in an €825 million ($970 million) deal.
The Ameriprise agreement will add $124 billion in European assets under management and is set to complete in the fourth quarter, subject to regulatory approvals.
Ameriprise inks $850 million deal to acquire BMO s EMEA business
pionline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pionline.com Daily Mail and Mail on Sunday newspapers.
Lightyear Capital, Oak HC/FT, and Greater Sum Ventures Announce Sale of Therapy Brands to KKR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Kyowa Kirin North America, the Bedminster-based unit of Japan’s Kyowa Kirin Co. Ltd., said this week that it is continuing its business integration initiative, merging a pair of units to streamline its structure.
The pharmaceutical company said in a news release that it is merging its Kyowa Kirin Research and Kyowa Kirin Development companies into one business, called Kyowa Kirin Inc., as part of its ongoing North American Business Integration, or NABI, initiative.
The goal of the initiative is a simpler business structure and common set of processes and systems.
“The organizational changes we are making through NABI will help Kyowa Kirin North America deliver the full value of these (pipeline) opportunities,” Gary Zieziula, president of KKNA, said in a prepared statement. “Through NABI, we’re working to enable more efficient collaborations and business support for the functions that discover, develop and deliver first-in-class medicines that can have a profound impact o